These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 7628874

  • 1. Engineering high affinity humanized anti-p185HER2/anti-CD3 bispecific F(ab')2 for efficient lysis of p185HER2 overexpressing tumor cells.
    Zhu Z, Lewis GD, Carter P.
    Int J Cancer; 1995 Jul 28; 62(3):319-24. PubMed ID: 7628874
    [Abstract] [Full Text] [Related]

  • 2. Engineering a humanized bispecific F(ab')2 fragment for improved binding to T cells.
    Rodrigues ML, Shalaby MR, Werther W, Presta L, Carter P.
    Int J Cancer Suppl; 1992 Jul 28; 7():45-50. PubMed ID: 1428403
    [Abstract] [Full Text] [Related]

  • 3. Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms.
    Link BK, Kostelny SA, Cole MS, Fusselman WP, Tso JY, Weiner GJ.
    Int J Cancer; 1998 Jul 17; 77(2):251-6. PubMed ID: 9650561
    [Abstract] [Full Text] [Related]

  • 4. Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene.
    Shalaby MR, Shepard HM, Presta L, Rodrigues ML, Beverley PC, Feldmann M, Carter P.
    J Exp Med; 1992 Jan 01; 175(1):217-25. PubMed ID: 1346155
    [Abstract] [Full Text] [Related]

  • 5. The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy.
    Weiner GJ, Kostelny SA, Hillstrom JR, Cole MS, Link BK, Wang SL, Tso JY.
    J Immunol; 1994 Mar 01; 152(5):2385-92. PubMed ID: 8133049
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Valency of CD3 binding and internalization of the CD3 cell-surface complex control T cell responses to second signals: distinction between effects on protein kinase C, cytoplasmic free calcium, and proliferation.
    Ledbetter JA, June CH, Martin PJ, Spooner CE, Hansen JA, Meier KE.
    J Immunol; 1986 Jun 01; 136(11):3945-52. PubMed ID: 3084650
    [Abstract] [Full Text] [Related]

  • 16. Engineering linear F(ab')2 fragments for efficient production in Escherichia coli and enhanced antiproliferative activity.
    Zapata G, Ridgway JB, Mordenti J, Osaka G, Wong WL, Bennett GL, Carter P.
    Protein Eng; 1995 Oct 01; 8(10):1057-62. PubMed ID: 8771187
    [Abstract] [Full Text] [Related]

  • 17. Chimeric bispecific OC/TR monoclonal antibody mediates lysis of tumor cells expressing the folate-binding protein (MOv18) and displays decreased immunogenicity in patients.
    Luiten RM, Warnaar SO, Sanborn D, Lamers CH, Bolhuis RL, Litvinov SV, Zurawski VR, Coney LR.
    J Immunother; 1997 Nov 01; 20(6):496-504. PubMed ID: 9409456
    [Abstract] [Full Text] [Related]

  • 18. Increased lysis of patient CD10-positive leukemic cells by T cells coated with anti-CD3 Fab' antibody cross-linked to anti-CD10 Fab' antibody.
    Oshimi K, Seto T, Oshimi Y, Masuda M, Okumura K, Mizoguchi H.
    Blood; 1991 Mar 01; 77(5):1044-9. PubMed ID: 1825287
    [Abstract] [Full Text] [Related]

  • 19. Localization of monoclonal antibody G250 and bispecific monoclonal antibody CD3/G250 in human renal-cell carcinoma xenografts: relative effects of size and affinity.
    van Dijk J, Zegveld ST, Fleuren GJ, Warnaar SO.
    Int J Cancer; 1991 Jul 09; 48(5):738-43. PubMed ID: 1830033
    [Abstract] [Full Text] [Related]

  • 20. [The enhancement of cytolytic activity in lymphokine activated killer cells using bispecific F(ab')2].
    Azuma A.
    Nihon Ika Daigaku Zasshi; 1991 Dec 09; 58(6):663-72. PubMed ID: 1663120
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.